TAS-303
/ Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
March 21, 2025
Breaking barriers in stress urinary incontinence care: TAS-303 as a game-changer in pharmacological innovation.
(PubMed, Transl Androl Urol)
- No abstract available
Journal • Urinary Incontinence • Urology
September 28, 2024
Re: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial.
(PubMed, Eur Urol)
- No abstract available
Clinical • Journal • P2 data • Urinary Incontinence • Urology
September 26, 2024
Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
(clinicaltrials.gov)
- P2 | N=337 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Phase classification: P2a ➔ P2 | N=256 ➔ 337
Enrollment change • Phase classification • Urinary Incontinence • Urology
August 22, 2024
Reply: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
(PubMed, J Urol)
- No abstract available
Clinical • Journal • P2 data • Urinary Incontinence • Urology
July 31, 2024
Letter: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
(PubMed, J Urol)
- No abstract available
Clinical • Journal • P2 data • Urinary Incontinence • Urology
July 09, 2024
Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
(PubMed, J Urol)
- P2 | "Once-daily TAS-303 18 mg showed superior efficacy to placebo for the treatment of SUI in Japanese women, with an adequate safety profile. ClinicalTrials.gov: NCT04512053; Japan Registry of Clinical Trials: jRCT2080225307 (JapicCTI-205403 before site integration)."
Clinical • Journal • P2 data • Gastrointestinal Disorder • Urinary Incontinence • Urology • Women's Health
August 07, 2023
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
(clinicaltrials.gov)
- P1 | N=6 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion
November 18, 2022
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
(clinicaltrials.gov)
- P1 | N=6 | Active, not recruiting | Sponsor: Taiho Pharmaceutical Co., Ltd.
New P1 trial
February 10, 2022
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
(clinicaltrials.gov)
- P2 | N=231 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: May 2022 ➔ Dec 2021 | Trial primary completion date: May 2022 ➔ Dec 2021
Trial completion • Trial completion date • Trial primary completion date • Urinary Incontinence • Urology
August 16, 2021
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
(clinicaltrials.gov)
- P2; N=186; Active, not recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting
Enrollment closed • Urinary Incontinence • Urology
February 16, 2021
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
(clinicaltrials.gov)
- P2; N=186; Recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Urinary Incontinence • Urology
April 28, 2020
TAS-303 ameliorates carbachol-induced detrusor overactivity in rats, revealing its therapeutic potential for overactive bladder.
(PubMed, J Pharmacol Exp Ther)
- "TAS-303 has therapeutic potential for stress urinary incontinence. This study describes newly discovered pharmacological properties of TAS-303, which ameliorated bladder afferent activity partly via M3 muscarinic inhibition, indicating improvement in urge urinary incontinence, and study highlights the potential of TAS-303 as a new therapeutic agent for all types of urinary incontinence."
Journal • Preclinical • Constipation • Overactive Bladder • Urinary Incontinence • Xerostomia
November 05, 2020
Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial.
(PubMed, Int J Urol)
- "These findings suggest that TAS-303 is effective for improving stress urinary incontinence symptoms in some subgroups of patients with stress urinary incontinence. Therefore, further research is warranted."
Clinical • Journal • P2 data • Cardiovascular • Urinary Incontinence • Urology • Women's Health
August 13, 2020
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
(clinicaltrials.gov)
- P2; N=186; Not yet recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.
Clinical • New P2 trial • Urinary Incontinence
1 to 14
Of
14
Go to page
1